Nanoviricides Inc (NNVC)

$2.4

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Nanoviricides Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 271.1%

Performance

  • $2.22
    $2.45
    $2.40
    downward going graph

    7.42%

    Downside

    Day's Volatility :9.32%

    Upside

    2.04%

    downward going graph
  • $1.00
    $2.49
    $2.40
    downward going graph

    58.33%

    Downside

    52 Weeks Volatility :59.84%

    Upside

    3.61%

    downward going graph

Returns

PeriodNanoviricides IncIndex (Russel 2000)
3 Months
98.35%
0.0%
6 Months
104.08%
0.0%
1 Year
105.13%
0.0%
3 Years
-36.0%
-22.6%

Highlights

Market Capitalization
28.4M
Book Value
$0.9
Earnings Per Share (EPS)
-0.82
PEG Ratio
0.0
Wall Street Target Price
6.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-40.78%
Return On Equity TTM
-65.85%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-9.0M
Diluted Eps TTM
-0.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.67
EPS Estimate Next Year
-0.9
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Nanoviricides Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 170.83%

Current $2.40
Target $6.50

Technicals Summary

Sell

Neutral

Buy

Nanoviricides Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nanoviricides Inc
Nanoviricides Inc
71.43%
104.08%
105.13%
-36.0%
-52.38%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nanoviricides Inc
Nanoviricides Inc
NA
NA
0.0
-0.67
-0.66
-0.41
NA
0.9
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nanoviricides Inc
Nanoviricides Inc
Buy
$28.4M
-52.38%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Company Information

nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir

Organization
Nanoviricides Inc
Employees
7
CEO
Dr. Anil R. Diwan Ph.D.
Industry
Health Technology

FAQs